ALGS (Aligos Therapeutics, Inc.) — Stock Analysis, Catalysts & AI Research

Aligos Therapeutics, Inc.

$6.23

The Read: Aligos Therapeutics' stock declined about 12% after Q1 2026 earnings met expectations but failed to ease cash concerns, then dropped another 10% when HBV cure data showing 40% response was viewed as underwhelming.

Price

Overlays

Panel

ALGS

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Aligos Therapeutics, Inc.

$6.23

Health CareBiotechnology

Price

Overlays

Panel

ALGS

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for ALGS

Expected Moves

Aligos Therapeutics, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for ALGS

Expected Moves

Aligos Therapeutics, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow